Sells oral medicines for anemia and other complications of kidney disease to people with kidney disease.
10-K for FY2025, filed Feb 26, 2026We are a fully integrated biopharmaceutical company with two commercial products for patients impacted by kidney disease. We have built a…View ↗
Vafseo® (vadadustat) is an orally administered medicine that was approved by the U.S. Food and Drug Administration, or the FDA, in March…View ↗
Auryxia® (ferric citrate) is an orally administered medicine approved and marketed in the U.S. for two indications: (1) the control of…View ↗
Akebia sells Auryxia and Vafseo to customers, who pay when they receive the products. Partners also pay upfront license fees when they receive rights, milestone payments and royalties on licensed-product sales, and Akebia earns revenue from products it supplies to partners.
10-K for FY2025, filed Feb 26, 2026The Company recognizes revenue on product sales when the customer obtains control of the Company’s products, which occurs at a point in…View ↗
The Company enters into license and collaboration agreements within the scope of ASC 606, under which it licenses certain rights to its…View ↗
If the license to the Company’s intellectual property is determined to be distinct from the other performance obligations identified in the…View ↗
At the inception of each arrangement that includes development milestone payments, the Company evaluates whether the milestones are…View ↗
$236.2M
10-K for FY2025, filed Feb 26, 2026
$236.2M ↗| Segment | Share | Revenue | How money arrives |
|---|---|---|---|
|
Product revenue, net
Sold outright
10-K for FY2025, filed Feb 26, 2026 |
96%
FY2022: 60%
|
Product revenue, net, FY2025
$227.3M Sources
|
Sold outright |
|
License, collaboration and other revenue
|
3.8%
FY2022: 40%
|
License, collaboration and other revenue, FY2025
$8.9M Sources
|
Dialysis organizations and distribution customers buy Auryxia and Vafseo for resale to healthcare providers and patients; partners pay Akebia under license, collaboration and product-supply agreements.
10-K for FY2025, filed Feb 26, 2026We generate product revenue from commercial sales of Auryxia and Vafseo to a limited number of customers, including dialysis organizations…View ↗
The Company recognizes product revenues on sales of Auryxia and Vafseo primarily attributable to a limited number of customers, including…View ↗
License, collaboration and other revenue includes revenue earned under our agreements with our partners, including license fees, royalty…View ↗
Not on paper. It lost $5.3M in FY2025, but brought in more cash than it spent: $67.7M of free cash flow.
10-Q for Q3 FY2026, filed Nov 5, 2026
−$14.4MView ↗
10-Q for Q3 FY2026, filed Nov 5, 2026
Open tableView ↗
8-K, filed Oct 23, 2026
The Notice has no immediate effect on the listing of the Company’s Common Stock. In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the…View ↗
Vafseo reached the U.S. market
Vafseo moved from a medicine under U.S. regulatory review to a U.S.-marketed treatment for anemia in adults on dialysis.
10-K for FY2022, filed Mar 10, 2023 10-K for FY2025, filed Feb 26, 2026Vafseo® (vadadustat) is an orally administered medicine that was approved by the U.S. Food and Drug Administration, or the FDA, in March…View ↗
Competes with Amgen, Johnson & Johnson, CSL Vifor, Astellas Pharma, Teva Pharmaceuticals, Stada Arzneimittel, Hexal, Sandoz, Roche, Bayer HealthCare, Sanofi, Fresenius Medical Care North America, Shire Pharmaceuticals Group, OPKO Health, Unicycive, and Ardelyx
10-K for FY2025, filed Feb 26, 2026Drugs that compete with Vafseo include Epogen® (epoetin alfa) and Aranesp® (darbepoetin alfa), both commercialized by Amgen, Procrit®…View ↗
Loading...